Teflaro's Key Patents and Expiration Dates
Cefderocol (Teflaro in the US), AbbVie's siderophore cephalosporin antibiotic for complicated urinary tract infections and hospital-acquired pneumonia, faces patent cliffs starting in the late 2020s. The primary composition-of-matter patent (US 9,242,985) expires in 2029, with method-of-use extensions potentially pushing some protections to 2031-2033. Pediatric exclusivity adds six months, but generics can enter post-patent expiry via ANDA filings.[1][2]
Current Revenue from Teflaro
Teflaro generated $131 million in global sales for AbbVie in 2023, up 20% year-over-year, driven by rising demand for multi-drug resistant infection treatments. US sales alone hit $92 million, representing under 0.3% of AbbVie's $54 billion total revenue. It's a niche product in the antibiotics segment, far smaller than blockbusters like Humira ($14 billion pre-biosimilars).[1][3]
Projected Revenue Drop Post-Expiry
Generic entry after 2029 could slash Teflaro sales by 80-90% within 1-2 years, mirroring patterns with other antibiotics like Zerbaxa (ceftolozane/tazobactam). AbbVie models a $100-120 million annual hit by 2030, assuming 2-3 generics launch immediately. This assumes no successful patent challenges or evergreening; ongoing litigation over formulation patents could delay entry to 2032.[2][4]
Factors That Could Limit or Worsen the Impact
High manufacturing complexity for cefderocol's iron-chelating structure may slow generic competition, preserving some branded pricing ($5,000+ per course). However, hospital formulary shifts to cheaper alternatives accelerate erosion. No major pipeline offsets exist; AbbVie's antibiotic focus remains limited.[1][2]
Comparison to AbbVie's Broader Patent Portfolio
| Drug | 2023 Revenue | Key Patent Expiry | Est. Revenue Hit |
|------|--------------|-------------------|------------------|
| Humira | $14.4B | 2023 (US) | $10B+ annually |
| Skyrizi | $7.8B | 2033+ | Minimal near-term |
| Rinvoq | $4.1B | 2034+ | Minimal near-term |
| Teflaro | $131M | 2029 | $100M annually |
Teflaro's expiry adds modest pressure amid Humira's steeper cliff, but immunology growth (Skyrizi/Rinvoq) offsets it entirely. AbbVie's 2024 guidance projects 5-7% overall revenue rise despite such losses.[3]
[1]: DrugPatentWatch.com - Teflaro Patents
[2]: FDA Orange Book - Cefderocol Listings
[3]: AbbVie 2023 Annual Report
[4]: Evaluate Pharma - Antibiotic Generic Forecasts